Patients undergo first doses of GE HealthCare's PET radiotracer Flyrcado (flurpiridaz F 18) injection at early adopter sites ...

GE HealthCare (GEHC) has delivered the first patient doses of Flyrcado or flurpiridaz F 18 njection, a first-of-its-kind unit dose positron ...

GE HealthCare has delivered the initial subject doses of Flyrcado (flurpiridaz F 18) injection, for coronary artery disease ...

Discover GE HealthCare's Q4 2024 insights: record $19.8B backlog, 18.7% margin growth, and Flyrcado's 2025 launch.

February 13, 2025GE HealthCare Technologies Inc. beats earnings expectations. Reported EPS is $1.45, expectations were $1.26.

For example, our cath lab, Allia IGS Pulse is outperforming our expectations and we're on track to launch Flyrcado in the near term. We continued to advance our leadership position in AI. In one year, ...

The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...

September 2024: The U.S. Food and Drug Administration cleared GE HealthCare's diagnostic medicine, Flyrcado, to detect coronary artery disease through PET myocardial perfusion imaging. Flyrcado ...

Wide-moat GE HealthCare, or GEHC, is a top three global leader in the medical imaging market. It has a firmly established footprint in hospitals and health networks around the world, and it is ...